| Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models IY Hwang, E Koh, A Wong, JC March, WE Bentley, YS Lee, MW Chang Nature communications 8 (1), 15028, 2017 | 390 | 2017 |
| Reprogramming microbes to be pathogen-seeking killers IY Hwang, MH Tan, E Koh, CL Ho, CL Poh, MW Chang ACS synthetic biology 3 (4), 228-237, 2014 | 198 | 2014 |
| Microbiome and human health: current understanding, engineering, and enabling technologies N Aggarwal, S Kitano, GRY Puah, S Kittelmann, IY Hwang, MW Chang Chemical reviews 123 (1), 31-72, 2022 | 105 | 2022 |
| Tweak to treat: reprograming bacteria for cancer treatment BFL Sieow, KS Wun, WP Yong, IY Hwang, MW Chang Trends in cancer 7 (5), 447-464, 2021 | 98 | 2021 |
| Engineering probiotics for therapeutic applications: recent examples and translational outlook N Aggarwal, AME Breedon, CM Davis, IY Hwang, MW Chang Current opinion in biotechnology 65, 171-179, 2020 | 88 | 2020 |
| Reprogramming Probiotic Lactobacillus reuteri as a Biosensor for Staphylococcus aureus Derived AIP-I Detection D Lubkowicz, CL Ho, IY Hwang, WS Yew, YS Lee, MW Chang ACS Synthetic Biology 7 (5), 1229-1237, 2018 | 69 | 2018 |
| Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria IY Hwang, E Koh, HR Kim, WS Yew, MW Chang Drug Resistance Updates 27, 59-71, 2016 | 48 | 2016 |
| Engineering probiotics to inhibit Clostridioides difficile infection by dynamic regulation of intestinal metabolism E Koh, IY Hwang, HL Lee, R De Sotto, JWJ Lee, YS Lee, JC March, ... Nature Communications 13 (1), 3834, 2022 | 44 | 2022 |
| Targeted approaches for in situ gut microbiome manipulation HL Lee, H Shen, IY Hwang, H Ling, WS Yew, YS Lee, MW Chang Genes 9 (7), 351, 2018 | 44 | 2018 |
| Engineering commensal bacteria to rewire host–microbiome interactions IY Hwang, MW Chang Current opinion in biotechnology 62, 116-122, 2020 | 35 | 2020 |
| Engineered microbial systems for advanced drug delivery H Shen, N Aggarwal, KS Wun, YS Lee, IY Hwang, MW Chang Advanced Drug Delivery Reviews 187, 114364, 2022 | 29 | 2022 |
| Engineering microbes for targeted strikes against human pathogens IY Hwang, HL Lee, JG Huang, YY Lim, WS Yew, YS Lee, MW Chang Cellular and Molecular Life Sciences 75, 2719-2733, 2018 | 23 | 2018 |
| Biotherapeutic approaches in atopic dermatitis EH Tham, E Koh, JEA Common, IY Hwang Biotechnology Journal 15 (10), 1900322, 2020 | 21 | 2020 |
| Therapeutic reactivation of mutant p53 protein by quinazoline derivatives HS Sutherland, IY Hwang, ES Marshall, BS Lindsay, WA Denny, ... Investigational new drugs 30, 2035-2045, 2012 | 18 | 2012 |
| Designing a synthetic genetic circuit that enables cell density-dependent auto-regulatory lysis for macromolecule release TM Lo, MH Tan, IY Hwang, MW Chang Chemical Engineering Science 103, 29-35, 2013 | 15 | 2013 |
| Development of a proline-based selection system for reliable genetic engineering in Chinese hamster ovary cells T Sun, WC Kwok, KJ Chua, TM Lo, J Potter, WS Yew, JD Chesnut, ... ACS Synthetic Biology 9 (7), 1864-1872, 2020 | 11 | 2020 |
| Matrix-immobilized yeast for large-scale production of recombinant human lactoferrin CL Ho, IY Hwang, K Loh, MW Chang MedChemComm 6 (3), 486-491, 2015 | 11 | 2015 |
| Engineered probiotics modulate the endocannabinoid system IY Hwang, HR Kim, R De Sotto, MW Chang Biotechnology Notes 2, 33-38, 2021 | 10 | 2021 |
| An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflammations in in vitro Inflammatory Bowel Disease Models KJ Chua, H Ling, IY Hwang, HL Lee, JC March, YS Lee, MW Chang ACS Biomaterials Science & Engineering 9 (9), 5123-5135, 2022 | 9 | 2022 |
| Isolated nucleotide molecule and method of sensing and killing of pathogenic microorganism MW Chang, IY Hwang, MH Tan, E Koh US Patent 9,603,877, 2017 | 8 | 2017 |
